Man Group’s Vor Biopharma VOR Stock Holding History

Man Group’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-848	Closed	-$94K	–	1907
2022 Q4	$113K	Buy	+848	New	+$83.9K	﹤0.01%	1892

Other funds holding VOR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Man Group's VOR Position: Q1 2023 in Review

Man Group sold out of Vor Biopharma (VOR) in Q1 2023, closing a stake of 848 shares — an estimated $94K sold.

Man Group first reported a position in VOR in Q4 2022 and held it in 1 quarter. The position peaked at $113K in Q4 2022. 59 funds tracked by Wall St. Rank hold VOR as of Q1 2023.

Man Group reported no remaining Vor Biopharma position as of Q1 2023 after selling out during the quarter.
Man Group sold 848 Vor Biopharma shares in Q1 2023, an estimated $94K.
Man Group first reported a position in Vor Biopharma in Q4 2022 and held it in 1 quarter.
Man Group's Vor Biopharma position peaked at $113K in Q4 2022.
59 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.